Ivabradina Doc Generici (Ivabradine Hydrochloride)

Ivabradine selectively blocks the funny (If) current in the sino‑atrial node, the primary pacemaker of the heart. This inhibition slows the spontaneous depolarisation of pacemaker cells, leading to a reduction in heart rate while preserving myocardial contractile force and blood pressure.

The dosage of ivabradine is individualized by the prescribing clinician based on the patient’s heart rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary adjustments.

Safety data for ivabradine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting beta‑adrenergic receptors, preserving contractility and blood pressure. Beta‑blockers have broader cardiovascular effects, including reduced contractility and blood pressure, which may be advantageous or limiting depending on the patient’s condition.

Ivabradine tablets should be stored below 25 °C in a dry place. Keep them in the original packaging to protect from moisture and light. Do not store in the bathroom or near heat sources, and keep out of reach of children.

Ivabradine is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not chewed or crushed, to ensure consistent absorption.

The most serious risks include severe bradycardia, which can cause dizziness, fatigue, or syncope, and atrial fibrillation, which may require medical intervention. Persistent visual disturbances and hypotension are also considered serious and should be reported promptly.

Ivabradine is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, acute decompensated heart failure, or a resting heart rate below 60 bpm. It should also be avoided in individuals taking strong CYP3A4 inhibitors unless dose adjustments are made under medical supervision.